ETNB

89bio (ETNB)

About 89bio (ETNB)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Details

Daily high

$9.75

Daily low

$8.80

Price at open

$8.90

52 Week High

$11.84

52 Week Low

$4.16

Market cap

1.3B

Dividend yield

0.00%

Volume

3.7M

Avg. volume

1.8M

P/E ratio

-2.67

89bio News